Journal of Clinical Endocrinology & Metabolism, Vol 81, 1389-1396, Copyright © 1996 by Endocrine Society

ARTICLES

Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): Development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids

Y Honda, EC Landale, DD Strong, DJ Baylink and S Mohan
Department of Medicine, Loma Linda University, California 92357, USA.

Insulin-like growth factor-binding protein-4 (IGFBP-4), like the five other IGFBPs present in human serum, acts as a transport protein for insulin-like growth factor I (IGF-I) and IGF-II and modulates their biological effects. To investigate the role of IGFBP-4 in the physiology of the IGF system, we developed a sensitive RIA for IGFBP-4 employing, as antigen, tracer, and standard, recombinant human IGFBP-4 (rhIGFBP-4) expressed in Escherichia coli as a fusion protein with glutathione S-transferase and affinity purified with glutathione- derivatized resin. Antibody against the rhIGFBP-4 fusion protein was raised in guinea pigs; tracer and standard were provided by the rhIGFBP- 4 moiety that had been cleaved from the rhIGFBP-4 fusion protein and repurified by reverse phase high pressure liquid chromatography. We report that both IGFBP-4 purified from PC3 human prostate cell- conditioned medium and rhIGFBP-4 bound IGF and migrated in electrophoresis gels in an identical manner; that in gel permeation chromatography, rhIGFBP-4 coeluted with the IGFBP-4 present in human serum; and that both are equally immunoreactive with the IGFBP-4 antiserum. Employing this IGFBP-4 RIA, we determined that no IGFBP other than IGFBP-4 reacted with the IGFBP-4 antiserum, and that recovery of IGFBP-4 from serum samples exceeded 90% when exogenous IGFBP-4 was added and was unaffected by the addition of IGFs or by repeated freezing and thawing of the sample. We employed this IGFBP-4 RIA to demonstrate an increase in IGFBP-4 in TE85 human osteosarcoma cell-conditioned medium after treatment with dibutyryl cAMP, PTH, and 1,25-dihydroxyvitamin D3, agents known to increase the IGFBP-4 messenger ribonucleic acid level. Application of this RIA to the measurement of IGFBP-4 in human serum revealed that the circulating level of IGFBP-4 in 41 individuals in the 61-87 yr age group (546 +/- 135 microgram/L) was 35% higher than that in 24 individuals in the 23- 40 yr age group (404 +/- 156 microgram/L). The mean circulating level of PTH was also 20% higher in the 61-87 yr group compared to that in the 23-40 yr group (P < 0.01). In addition, serum IGFBP-4 amounts showed a significant positive correlation with age (r = 0.54; P < 0.001) and serum PTH (r = 0.26; P < 0.01). These data validate this IGFBP-4 RIA and illustrate its utility in illuminating the physiological mechanisms that regulate IGFBP-4 in vivo and influence its effects on the IGFs in both normal and abnormal pathology and in aging.

This article has been cited by other articles:

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				R. P A Rooman, L. O. De Beeck, M. Martin, J. van Doorn, S. Mohan, and M. V L Du Caju Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature Eur. J. Endocrinol., April 1, 2005; 152(4): 597 - 604. [Abstract] [Full Text] [PDF]

				C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300. [Abstract] [Full Text] [PDF]

				A. Eliakim, T. P. Scheett, R. Newcomb, S. Mohan, and D. M. Cooper Fitness, Training, and the Growth Hormone{->}Insulin-Like Growth Factor I Axis in Prepubertal Girls J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2797 - 2802. [Abstract] [Full Text] [PDF]

				N. Miyakoshi, X. Qin, Y. Kasukawa, C. Richman, A. K. Srivastava, D. J. Baylink, and S. Mohan Systemic Administration of Insulin-Like Growth Factor (IGF)-Binding Protein-4 (IGFBP-4) Increases Bone Formation Parameters in Mice by Increasing IGF Bioavailability via an IGFBP-4 Protease-Dependent Mechanism Endocrinology, June 1, 2001; 142(6): 2641 - 2648. [Abstract] [Full Text] [PDF]

				R. Fernholm, M. Bramnert, E. Hägg, A. Hilding, D. J. Baylink, S. Mohan, and M. Thorén Growth Hormone Replacement Therapy Improves Body Composition and Increases Bone Metabolism in Elderly Patients with Pituitary Disease J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4104 - 4112. [Abstract] [Full Text]

				D. Byun, S. Mohan, C. Kim, K. Suh, M. Yoo, H. Lee, D. J. Baylink, and X. Qin Studies on Human Pregnancy-Induced Insulin-Like Growth Factor (IGF)-Binding Protein-4 Proteases in Serum: Determination of IGF-II Dependency and Localization of Cleavage Site J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 373 - 381. [Abstract] [Full Text]

				N. Miyakoshi, C. Richman, X. Qin, D. J. Baylink, and S. Mohan Effects of Recombinant Insulin-Like Growth Factor-Binding Protein-4 on Bone Formation Parameters in Mice Endocrinology, December 1, 1999; 140(12): 5719 - 5728. [Abstract] [Full Text]

				J. J. Smink, J. G. Koster, B. I. Hendriks-Stegeman, and S. C. van Buul-Offers Insulin-Like Growth Factor (IGF) II Induced Changes in Expression of IGF Binding Proteins in Lymphoid Tissues of hIGF-II Transgenic Mice Endocrinology, December 1, 1999; 140(12): 5876 - 5882. [Abstract] [Full Text]

				G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R. C. Baxter, J. D. Veldhuis, C. Y. Bowers, and R. Bouillon Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1311 - 1323. [Abstract] [Full Text]

				D. R. Powell, S. K. Durham, E. D. Brewer, J. W. Frane, S. L. Watkins, R. J. Hogg, and S. Mohan Effects of Chronic Renal Failure and Growth Hormone on Serum Levels of Insulin-Like Growth Factor-Binding Protein-4 (IGFBP-4) and IGFBP-5 in Children: A Report of the Southwest Pediatric Nephrology Study Group J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 596 - 601. [Abstract] [Full Text]

				D. Storm, R. E. E. S. Porter, K. Musgrave, D. Vereault, C. Patton, C. Kessenich, S. Mohan, T. Chen, M. F. Holick, and C. J. Rosen Calcium Supplementation Prevents Seasonal Bone Loss and Changes in Biochemical Markers of Bone Turnover in Elderly New England Women: A Randomized Placebo-Controlled Trial J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3817 - 3825. [Abstract] [Full Text]

				A. Eliakim, J. A. Brasel, S. Mohan, W. L. T. Wong, and D. M. Cooper Increased physical activity and the growth hormone-IGF-I axis in adolescent males Am J Physiol Regulatory Integrative Comp Physiol, July 1, 1998; 275(1): R308 - R314. [Abstract] [Full Text] [PDF]

				S. M. Twigg and R. C. Baxter Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile Subunit J. Biol. Chem., March 13, 1998; 273(11): 6074 - 6079. [Abstract] [Full Text] [PDF]

				G. L. Klein, S. E. Wolf, C. B. Langman, C. J. Rosen, S. Mohan, B. S. Keenan, S. Matin, C. Steffen, M. Nicolai, D. E. Sailer, et al. Effect of Therapy with Recombinant Human Growth Hormone on Insulin-Like Growth Factor System Components and Serum Levels of Biochemical Markers of Bone Formation in Children After Severe Burn Injury J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 21 - 24. [Abstract] [Full Text]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]